Coripharma is pleased to announce the successful completion of development for Ivacaftor tablets in 75mg and 150mg strengths. The company has achieved positive results from both fed and fasted pivotal bioequivalence studies, marking a significant milestone in bringing this important cystic fibrosis treatment to the generic pharmaceutical market.
